

60 ~~sec'd~~ PCT/PTO 21 SEP 2001
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
MARCIREAU ET AL.

Examiner: UNASSIGNED

Serial No.: **09/744,125**

Art Unit: UNASSIGNED

Filed: JANUARY 19, 2001

Title: **MEKK1-INTERACTING FHA
PROTEIN (M1F1)**

5060

Handwritten signature/initials

STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)

Commissioner for Patents
Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed copy of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the enclosed copy of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Sequence Listing can be found in the instant Application as filed.

Respectfully submitted,

Handwritten signature of William C. Coppola

William C. Coppola, Reg. No. 41,686
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626
Docket No. A3233A US